Von Willebrand factor propeptide and the occurrence of a first ischemic stroke

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 6, 2010, Pages 1424-1426

  Van Schie, M C ^a   De Maat, M P M ^a   Dippel, D W J ^b   de Groot, P G ^a   Lenting, P J ^a   Leebeek, F W G ^a   Hollestelle, M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPEPTIDE;

BRAIN ISCHEMIA; CARDIOVASCULAR RISK; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; STROKE; VON WILLEBRAND FACTOR;

EID: 77954530708     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03863.x     Document Type: Letter

References (11)

1. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999, 100:736-42.
2. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996, 84:289-97.
3. Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EK. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost 1997, 77:387-93.
4. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998, 67:395-424.
5. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996, 88:2951-8.
6. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A 1987, 84:1955-9.
7. Nossent AY, van Marion V, van Tilburg NH, Rosendaal FR, Bertina RM, van Mourik JA, Eikenboom HC. Von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006, 4:2556-62.
8. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005, 3:2211-8.
9. de Bruijne EL, Gils A, Guimaraes AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW. The role of thrombin activatable fibrinolysis inhibitor (TAFI) in arterial thrombosis at young age: the ATTAC study. J Thromb Haemost 2009, 7:919-27.
10. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, Fressinaud E, van den Berg HM, de Groot PG, Lenting PJ. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007, 109:2430-7.
11. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gomez Garcia EB, Dippel DW, Leebeek FW. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37:2672-7.